The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

Hypoxia-inducible factors (HIFs) and the HIF-dependent cancer hallmarks angiogenesis and
metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy …

Breast cancer is the most commonly occurring cancer in women. There were over two-
million new cases in world in 2018. It is the second leading cause of death from cancer in …

Abstract Estrogen receptor-positive (ER+) breast cancer accounts for approximately 75% of
all breast cancers. Endocrine therapies, including selective ER modulators (SERMs) …

FOXA1, a transcription factor involved in epigenetic reprogramming, is crucial for breast
cancer progression. However, the mechanisms by which FOXA1 achieves its oncogenic …

Abstract FOXA1 (Forkhead Box A1) and FOXA2 (Forkhead Box A2) serve as pioneering
transcription factors that build gene expression capacity and play a central role in biological …

Rationale: The forkhead box A1 (FOXA1) is a crucial transcription factor in initiation and
development of breast, lung and prostate cancer. Previous studies about the FOXA1 …

Transcriptional super-enhancers and the BET bromodomain protein BRD4 are emerging as
critical drivers of tumorigenesis and therapeutic targets. Characterized by substantial …

The progression of cancer involves not only the gradual evolution of cells by mutations in
DNA but also alterations in the gene expression induced by those mutations and input from …